Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease

Archives of Neurology

Volumn 64, Issue 7, 2007, Pages 938-944

  Storch, Alexander ^a,b   Jost, Wolfgang H ^c   Vieregge, Peter ^d   Spiegel, Jörg ^e   Greulich, Wolfgang ^f   Durner, Joachim ^g   MüLler, Thomas ^h   Kupsch, Andreas ⁱ   Henningsen, Henning ^j   Oertel, Wolfgang H ^k   Fuchs, Gerd ^g   Kuhn, Wilfried ^l   Niklowitz, Petra ^m   Koch, Rainer ^b,n   Herting, Birgit ^b   Reichmann, Heinz ^b  

^a UNIVERSITY OF ULM   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^d KLINIKUM LIPPE DETMOLD   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f Department of Neurology   (Germany)

^g Fachklinik Ichenhausen ^*  (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Dept of Neurology   (Germany)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l Leopoldina Krankenhaus   (Germany)

^m UNIVERSITY OF WITTEN HERDECKE   (Germany)

ⁿ MSE Pharmazeutika GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NANOPARTICLE; PLACEBO; UBIDECARENONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HALLUCINATION; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; STRATIFICATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIOXIDANTS; CELL RESPIRATION; COENZYMES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENERGY METABOLISM; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PLACEBOS; SUBSTANTIA NIGRA; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 34447252358     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.7.nct60005     Document Type: Article

References (28)

1. Lang AE, Lozano AM. Parkinson's disease: first of two parts. N Engl J Med. 1998;339(15):1044-1053.
2. Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr. 2004;36(4):375-379.
3. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem. 1990;55(5):1810-1812.
4. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 1990;55(6):2142-2145.
5. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271(1):195-204.
6. Echtay KS, Winkler E, Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature. 2000;408(6812):609-613.
7. Beal MF. Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. Methods Enzymol. 2004;382:473-487.
8. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783(1):109-114.
9. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol. 2004;27(4):187-191.
10. Marriage BJ, Clandinin MT, Macdonald IM, Glerum DM. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab. 2004;81(4):263-272.
11. Bresolin N, Bet L, Binda A, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology. 1988;38(6):892-899.
12. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
13. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341(3):201-204.
14. Horstink MW, van Engelen BG. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol. 2003;60(8):1170- 1172.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
16. Fahn S, Elton RL. UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163,293-304.
17. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26(5):353-357.
18. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
19. Niklowitz P, Menke T, Wiesel T, et al. Coenzyme Q10 in plasma and erythrocytes: comparison of antioxidant levels in healthy probands after oral supplementation and in patients suffering from sickle cell anemia. Clin Chim Acta. 2002;326(1-2):155-161.
20. Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002;17(2):283-288.
21. Jimenez-Jimenez FJ, Molina JA, de Bustos F, et al. Serum levels of coenzyme Q10 in patients with Parkinson's disease. J Neural Transm. 2000;107(2):177-181.
22. de Bustos F, Molina JA, Jimenez-Jimenez FJ, et al. Serum levels of coenzyme Q10 in patients with Alzheimer's disease. J Neural Transm. 2000;107(2):233-239.
23. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004;188(2):491-494.
24. Lass A, Sohal RS. Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 2000;14(1):87-94.
25. Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol. 2005;62(2):317-320.
26. Gille G, Hung ST, Reichmann H, Rausch WD. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann N Y Acad Sci. 2004;1018:533-540.
27. Winkler-Stuck K, Wiedemann FR, Wallesch CW, Kunz WS. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. J Neurol Sci. 2004;220(1-2):41-48.
28. Rosenfeldt F, Marasco S, Lyon W, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg. 2005;129(1):25-32.